Fabrizi F, Donato FM, Messa P

Idioma: Ingles.
Referencias bibliográficas: 230
Paginas: 364-391
Archivo PDF: 281.03 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987; 83: 726-30.

2. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991; 78: 3142-7.

3. Johnson R, Gretch D, Yamabe H, Hart J, Bacchi C, Hartwell P, Couser W, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-70.

4. Johnson R, Gretch D, Couser WG, Alpers C, Wilson J, Chung M, Hart J, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-04.

5. Dammacco F, Sansonno D, Han J, Shymala V, Cornacchiulo V, Iacobelli A, Lauletta G, et al. Natural interferon alpha versus its combination with 6-methylprednisolone in the therapy of type II mixed cryoglobulinemia: a long-term randomized cross-over controlled trial. Blood 1994; 84: 3336-43.

6. Pucillo LP, Agnello V. Membranoproliferative glomerulonephritis associated with hepatitis B and C viral infections: from virus like particles in the cryoprecipitate to viral localization in paramesangial deposits, problematic investigations prone to artifacts. Curr Opin Nephrol Hypertens 1994; 3: 465-70.

7. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi P, Zilio P, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.

8. Davis C, Gretch D, Perkins J, Harris A, Wener M, Alpers C, Lesniewski R, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transplant Surg 1995; 1: 166-75.

9. Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumathol 1995; 13 (Suppl. 13): S175-S180.

10. Altraif I, Abdulla A, Al Sebayel M, Said R, Al Suhaibani M, Jones A. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995; 15: 407-10.

11. Yamabe H, Johnson R, Gretch D, Osawa H, Inuma H, Sasaki T, Kaizuka M, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus responsive to interferon-alpha. Am J Kidney Dis 1995; 25: 67-9.

12. Stehman-Breen C, Willson R, Alpers C, Gretch D, Johnson R. Hepatitis C virus associated glomerulonephritis. Curr Opin Nephrol Hypertens 1995; 4: 287-94.

13. Roth D. Hepatitis C virus: the nephrologist’s view. Am J Kidney Dis 1995; 25: 3-16.

14. Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 1996; 35: 529-33.

15. Gilli P, Stabellini N, Storari A, Gualandi G, Guerra G, Ghinelli F. Effect of human leukocyte alpha interferon on cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996; 11: 526-8.

16. Morosetti M, Sciarra G, Meloni C, Palmieri G, Palombo G, Taccone-Gallucci M, Casciani C. Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon-alpha therapy on clinical out come and histological pattern. Nephrol Dial Transplant 1996; 11: 532-4.

17. Matyus J, Kovacs J, Ujhelyi L, Karpati I, Dalmi L, Kakuk G. Interferon therapy in cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Orv Hetil 1996; 137: 2527-30.

18. Kendrick E, McVicar J, Kowdley K, Bronner M, Emond M, Alpers C, Gretch D, et al. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997; 63: 1287-93.

19. Moses P, Krawitz E, Aziz W, Corwin H. Renal failure associated with hepatitis C virus infection. Improvement in renal function after treatment with interferon-alpha. Dig Dis Sci 1997; 42: 443-6.

20. Sarac E, Bastacky S, Johnson J. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30: 113-5.

21. Casato M, Agnello V, Pucillo L, Knight G, Leoni M, Del Vecchio S, Mazzilli C, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-73.

22. Adinolfi L, Utili R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinemia. Eur J Gastroenterol Hepatol 1997; 29: 343-50.

23. Mazzaro C, Carniello G, Colle R, Doretto P, Mazzi G, Crovatto M, Santini G, et al. Interferon therapy in HCV-positive mixed cryoglobulinemia: viral and host factors contributing to efficacy of the therapy. Ital J Gastroenterol Hepatol 1997; 29: 343-50.

24. Pham H, Feray C, Samuel D, Gigou M, Azoulay D, Paradis V, Ducret F, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54: 1311-9.

25. Fabrizi F, Pozzi C, Farina M, Dattolo P, Lunghi G, Badalamenti S, Pagano A, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant 1998; 13: 1991-7.

26. D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-71.

27. Stehman-Breen C, Johnson R. Hepatitis C virus-associated glomerulonephritis. Adv Intern Med 1998; 43: 79-97.

28. Cresta P, Musset L, Cacoub P, Frangeoul L, Vitour D, Poynard T, Opolon P, et al. Response to interferon-alpha treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 1999; 45: 122-8.

29. Kiyomoto H, Hitomi H, Hosotani Y, Hashimoto M, Uchida K, Kurokoucji K, Nagai M, et al. The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection. Ther Apher 1999; 3: 329-33.

30. Misiani R, Bellavita P, Baio P, Caldara R, Ferruzzi S, Rossi S, Tengattini F. Successful treatment of HCV-associated cryoglobulinemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14: 1558-60.

31. Stehman-Breen C, Alpers C, Fleet W, Johnson R. Focal segmental sclerosis among patients infected with HCV. Nephron 1999; 81: 37-40.

32. Ezaki Y, Tanaka U, Minoshima S, Endou M, Kuwaki K, Arimura Y, Nakabayashi K, et al. Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy. Nippon Jinzo Gakkai Shi 1999; 41: 83-8.

33. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999; 106: 347-54.

34. Stehman-Breen C, Alpers C, Fleet W, Johnson R. Focal segmental sclerosis among patients infected with HCV. Nephron 1999; 81: 37-40.

35. Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999; 33: 1142-6.

36. Kiyomoto H, Hitomi H, Hosotani Y, Hashimoto M, Uchida K, Kurokouchi K, Nagai M, et al. The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection. Ther Apher 1999; 3: 329-33.

37. Calleja J, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, Yebra M, et al. Sustained response to interferonalpha or to interferon-alpha plus ribavirin in hepatitis C virus associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol Ther 1999; 13: 1179-86.

38. Nishi S, Ueno M, Shomada H, Oosawa Y, Iino N, Iguchi S, Karasawa R, et al. Treatment of membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nijgata Research Group of Glomerulonephritis and Nephrotic Syndrome. Intern Med 2000; 39: 788-93.

39. Matsumoto S, Nakjima S, Nakamura K, Etani Y, Hirai H, Shimizu N, Yokoyama H, et al. Interferon treatment on glomerulonephritis associated with hepatitis C virus. Pediatr Nephrol 2000; 15: 271-3.

40. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-15.

41. Laganovic M, Jelakovich B, Kuzmanic D, Ascukanec–Spoliar M, Roncevic T, Cuzic S, Ostojic R. Complete remission of cryoglobulinemic glomerulonephritis (HCV-positive) after high dose interferon therapy. Wien Klin Wochenschr 2000; 112: 596-600.

42. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K, Ogawa S, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11: 690-9.

43. Yamabe H. How do we treat patients with hepatitis C virus associated glomerulonephritis? Intern Med 2000; 39: 525-6.

44. Jefferson J, Johnson R. Treatment of hepatitis C associated glomerular disease. Semin Nephrol 2000; 20: 286-92.

45. Sinico R, Fornasieri A, D’Amico G. Renal manifestations associated with hepatitis C virus. Ann Med Interne 2000; 151: 41-5.

46. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-34.

47. Motta M, Malaguarnera M, Restuccia N, Romano M, Vinci E, Pistone G. Focal segmental glomerulosclerosis and hepatitis C virus: a case report. Panminerva Med 2001; 43: 49-52.

48. Suzuki T, Yonemura K, Miyaji T, Suzuki H, Takahira R, Fujigaki Y, Fujimoto T, et al. Progressive renal failure and blindness due to retinal haemorrhage after interferon therapy for hepatitis C virus-associated membrano-proliferative glomerulonephritis. Intern Med 2001; 40: 708-12.

49. Philipneri M, Bastani B. Kidney disease in patients with chronic hepatitis C. Curr Gastroenterol Rep 2001; 3: 79-83.

50. Mehta S, Levey J, Bonkovsky H. Extrahepatic manifestations of infection with hepatitis C virus. Clin Liver Dis 2001; 5: 979-1008.

51. Naarendorp M, Kallemuchikkal U, Nuovo G, Gorevic P. Long-term efficacy of interferon-alpha for extra-hepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28: 2466-73.

52. Dussol B, Moal V, Daniel L, Pin C, Berland Y. Spontaneous remission of HCV-induced cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2001; 16: 156-9.

53. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E35.

54. Lhotta K. Beyond hepatorenal syndrome: glomerulonephritis in patients with liver disease. Semin Nephrol 2002; 22: 302-8.

55. Sabry A, Sobh M, Sheashaa H, Kudesia G, Wild G, Fox S, Wagner B, et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002; 17: 1924-30.

56. Perez-Calvo J, Lasierra P, Moros M, Inigo P. Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C virus infection refractory to alpha-interferon. Nephron 2002; 92: 459-62.

57. Cacoub P. Treatment of extrahepatic manifestations associated with hepatitis C virus infection. Gastroenterol Clin Biol 2002; 26: B210-B219.

58. Mazzaro C, Colle R, Baracetti S, Nascimbeni F, Zorat F, Pozzato G. Effectiveness of leukocyte interferon in patients affected by HCV positive mixed cryoglobulinemia resistant to recombinant alpha-interferon. Clin Exp Rheumatol 2002; 20: 27-34.

59. Beddhu S, Bastacky S, Johnson P. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81: 398-403.

60. Guarnieri A, Marazzi F, Giorgi M, Canepari G, Pino C, Moggia E, Manca A, et al. Steroids, interferon-alpha and ribavirin treatment of cryoglobulinemic glomerulonephritis concurrent with HCV infection. Giorn It Nefrol 2002; 19: 79-81.

61. Fabrizi F, Colucci P, Ponticelli C, Locatelli F. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002; 22: 309-318.

62. Szczech L, Ganger S, van der Host C, Bartlett J, Young M, Cohen M, Anastos K, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202.

63. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C –associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-80.

64. Lopes E, Valente L, Silva E, Kirsztajn G, Cruz C, Hoofnagle J. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003; 7: 353-7.

65. Meyers C, Seeff L, Stehman-Breen C, Hoofnagle J. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.

66. Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, Bellavita P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-41.

67. Tedaldi E, Baker R, Moorman A, Alzola C, Furher J, McCabe R, Wood K, et al. Influence of co-infection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 363-7.

68. Ghinoi A, Mascia M, Puccini R, Ferri C. Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review). G Ital Nefrol 2004; 21: 225-37.

69. Alric L, Plaisier E, Thebault S, Peron J, Rostaing L, Pourrat J, Ronco P, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-23.

70. Szczech L, Gupta S, Habash R, Guasch A, Kalayjian R, Appel R, Fields T, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66: 1145-52.

71. Poordad F, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004; 24 (Suppl. 2): 69-77.

72. Vassalle C, Masini S, Bianchi F, Zucchelli G. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-6.

73. Matsumori A. Effect of IFN treatment for extrahepatic manifestations. Nihon Rinsho 2004; 62 (Suppl. 7): 569-73.

74. Uchiyama –Tanaka Y, Mori Y, Kishimoto N, Nose A, Kijima Y, Nagata T, Umeda Y, et al. Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review. Clin Nephrol 2004; 61: 144-50.

75. Orlent H, Mathot R, Van Bommel E, Vulto A, Schalm S, Brouwer J. Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type I. Dig Dis Sci 2005; 50: 1804-6.

76. Garini G, Allegri L, Vaglio A, Buzio C. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Intern Med 2005; 20: 71-80.

77. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506.

78. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int 2005; 67: 285-290.

79. Hu S, Jaber B. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005; 63: 41-5.

80. Crook E, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer survival in diabetic patients. Diabetes Care 2005; 28: 2187-91.

81. Cua I, Kwan V, Henriquez M, Kench J, George J. Long-term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut 2006; 55: 1521-2.

82. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link ? J Int Med 2006, 260: 255-62.

83. Tsui J, Vittinghoff E, Shlipak M, O’Hare A. Relationship between hepatitis C an chronic kidney disease: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-74.

84. Kamar N, Rosating L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69: 436-9.

85. Bruchfeld A, Lindahl K, Stahle L, Schvarcz R. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia. J Hepatol 2006; 44: 432-3.

86. Saadoun D, Resche-Rigon M, Thibault V, Piette J, Cacoub P. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006; 54: 3696-76.

87. Zeman M, Cambell P, Bain V. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20: 427-31.

88. Kayali Z, Labrecque D, Schmidt W. Treatment of hepatitis C cryoglobulinemia: mission and challenges. Curr Treat Options Gastroenterol 2006; 9: 497-507.

89. Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007; 30: 212-9.

90. Fabrizi F, Lunghi G, Ganeshan S, Martin P, Messa P. Hepatitis C virus infection and the dialysis patient. Semin Dial 2007; 20: 416-22.

91. Garini G, Allegri L, Iannuzzella F, Vaglio A, Buzio C. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007; 78: 51-9.

92. Roccatello D, Fornasieri D, Giachino O, Roccatello D, Rossi D, Beltrame A, Banfi G, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Am J Kidney Dis 2007; 49: 69-82.

93. Koziolek H, Scheel A, Bramlage C, Groene H, Mueller G, Strutz F. Effective treatment of hepatitis C-associated immune- complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 2007; 67: 245-9.

94. Tsui J, Vittinghoff E, Shlipak M, Bertenthal D, Inadomi J, Rodriguez R, O’Hare A. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Int Med 2007; 167: 1271-6.

95. Dalrymple L, Koepsell T, Sampson J, Louie T, Dominitz J, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2007; 2: 715-21.

96. Joshi S, Kuczynski M, Heathcote E. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulinemia. Dig Dis Sci 2007; 52: 2410-7.

97. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216-20.

98. Ahmed M, Wong C, Shawki H, Kapoor N, Pandya B. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol 2008; 69: 298-301.

99. Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C. The impact of hepatitis C virus-co-infection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS 2008; 22: 1789-807.

100. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol 2008; 49: 613-624.

101. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008; 21: 813-25.

102. Abbas G, Hussain S, Shafi T. Effect of antiviral therapy on hepatitis C virus related glomerulopathy. Saudi J Kindey Dis Transpl 2008; 19: 775-80.

103. Mangia A, Burra P, Ciancio A, Fagiuoli S, Guido M, Picciotto A, Fabrizi F, et al. Hepatitis C infection in patients with chronic kidney disease. Int J Artif Organs 2008; 31: 15-33.

104. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney International 2008; 73 (Suppl 109): S1–S99.

105. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatology Research 2008; 38: 775-83.

106. Alyan O, Kacmaz F, Ozdemir O, Deveci B, Astan R, Celebi A, Ilkay E. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72: 1960-5.

107. Iannuzzella F, Garini S. Current therapeutic strategies for HCV-associated cryoglobulinemia. Reumatismo 2008; 60: 163-73.

108. Moe S, Pampalone A, Ofner S, Rosenman M, Teal E, Hui S. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008; 51: 885-92.

109. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3: 25.

110. Sugiura T, Yamada T, Kimpara Y, Fuijta N, Goto K, Koyama N. Effects of pegylated interferon alpha-2a on hepatitis – C-virus associated glomerulonephritis. Pediatr Nephrol 2009; 24: 199-202.

111. Laurino S, Borrelli S, Catapano F, Mascia S, D’Angiò P, Calabria M, Grimaldi M, et al. Treatment of HCV-associated cryoglobulinemic glomerulonephritis. G Ital Nefrol 2009; 26: 318-27.

112. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Newicki M, Cohen M, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis 2009; 54: 43-50.

113. Lo K, Chen C, Lee C. Hepatitis C virus-associated type II mixed cryoglobulinemia vasculitis complicated with membranous proliferative glomerulonephritis. Ren Fail 2009; 31: 149-52.

114. Charles E, Dustin L. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-24.

115. Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol 2010; 6: 395- 403.

116. Asrani S, Buchanani P, Pinsky B, Rocca Rey L, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010; 8: 79-84.

117. Lee M, Yang H, Wang C, Jen C, Yeh S, Liu C. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-900.

118. Noureddine L, Usman S, Yu Z, Moorthl R, Moe S. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol 2010; 32: 311-6.

119. Lee J, Lin M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010; 56: 23-31.

120. Fabrizi F, Martin P, Messa P. Hepatitis B and hepatitis C virus and chronic kidney disease. Acta Gastroenterol Belg 2010; 73: 465-71.

121. Mima A, Iehara N, Matsubara T, Yamamoto S, Abe H, Nagai K, Matsura M, et al. Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient. Clin Nephrol 2010; 73: 167-9.

122. Ji F, Li Z, Ge H, Deng H. Successful interferon-alpha treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med 2010; 49: 2531-2.

123. Namba T, Shiba R, Yamamoto T, Hirai Y, Moriwaki T, Matsuda J, Kadoya H, et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010; 75: 374-9.

124. Derbala M, Shebl F, Rashid A, Amer A, Bener A. Microalbuminuria in hepatitis C-genotype 4: effect of pegylated interferon and ribavirin. World J Gastroenterol 2010; 16: 1226-31.

125. Mostafa A, Mohamed M, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59: 1135-40.

126. Fischer M, Wyatt C, Gordon K, Giber C, Brown S, Rimland D, Rodriguez-Barradas M, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010; 53: 222-6.

127. Arase Y, Suzuki F, Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatology Research 2011; 41: 946-54.

128. Aoufi Rabih S, Garcia Agudo R. Management of HCV infection in chronic kidney disease. Nefrologia 2011; 31: 260-7.

129. George E, Nadkharni G, Estrella M, Lucas G, Sperati J, Atta M, Fine D. The impact of hepatitis C co-infection on kidney disease related to human immunodeficiency virus. Medicine (Baltimore) 2011; 90: 89-295.

130. Flandre P, Pugliese P, Cuzin L, Bagnis I, Tack I, Cabiè A, Poizot-Martin I, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 2011; 6: 1700-7.

131. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Urinary albumin excretion within the normal range is an independent risk factor for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant 2011; 26: 3923-9.

132. Hofmann J, Torner A, Chow W, Ye W, Purdue M, Duberg A. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev 2011; 20: 326-30.

133. Butt A, Wang X, Fried L. HCV and the incidence of CKD. Am J Kidney Dis 2011; 57: 396-402.

134. Colucci G, Manno C, Grandaliano G, Schena F. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol 2011; 75: 374-9.

135. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 444-54.

136. Yanagisawa N, Ando M, Ajisawa A, Imamura A, Suganuma A, Tsuchiya K, Nitta K. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract 2011; 118: c291-c295.

137. Di Biagio A, Rosso R, Vitale F, Cardinale F, Sormani M, Secondo G, Di Stefano L, et al. Risk factors for chronic kidney disease amonh human immunodeficiency virus-infected patients: A European case control study. Clin Nephrol 2011; 75: 518-623.

138. Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao H, Zhang W, Wei L. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant 2012; 27: 640-6.

139. Su F, Su C, Chang S, Chen P, Sung F, Lin C, Yeh C. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis 2012; 60: 553-60.

140. Aoufi Rabih S, Agudo R, Burillo J, Carrillo F, Gonzalez P, Roldan F, Ferrus M, et al. Microalbuminuria and ren.al insufficiency in chronic hepatitis C virus infection. Gastroenterol Hepatol 2012; 35: 309-16.

141. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012; 7: 549-57.

142. Van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

143. Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012; 6: 369-77.

144. Fabrizi F, Fogazzi G, Cresseri D, Passerini P, Martin P, Donato M, Rumi G, et al. Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature. Kidney Blood Press Res 2012; 35: 687-93.

145. Peters L, Grint D, Lundgreen J, Rockstroh J, Soriano V, Reiss P, Grzeszczuk A, et al. Hepatitis C virus viremia increased the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012; 26: 1917-26.

146. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive antiretroviral-treated adults. PLos One 2012; 7: e40245.

147. Jotwani V, Li Y, Grunfeld C, Choi A, Shlipak M. Risk factors for ESRD in HIV- infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59: 628-35.

148. Kalayian R, Lau B, Mechekano R, Crane H, Rodriguez B, Salata R, Krishnasami Z, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26: 1907-15.

149. Donato M, Fabrizi F, Fogazzi G, Cresseri D, Passerini P, Martin P, Messa P. Remission of HCV-associated glomerulonephritis with pegylated interferon and ribavirin therapy after liver transplantation: case report and literature review. Int J Artif Organs 2013; 36: 63-8.

150. Sperati C. Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha- 2a and ribavirin. Clin Nephrol 2013; 80: 231-4.

151. Shah H, Patel C. Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis. Ren Fail 2013; 35: 1182-5.

152. Tang S, Lai K. Hepatitis C virus-associated glomerulonephritis. Contr Nephrol 2013; 181: 194-206.

153. Bahirwani R, Barin B, Olthoff K, Stock P, Murphy B, Reddy R, for the Solid Organ Transplantation in HIV: Multi-Site Investigators. Chronic kidney disease after liver transplantation in human immunodeficiency virus /hepatitis C virus co-infected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health Multi-Site Study. Liver Transplant 2013; 19: 619-28.

154. Estrella M, Wyatt C, Pearce C, Li M, Shlipak M, Gustafson D, Cohen M, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84: 834-40.

155. Reynes J, Cournil A, Peyriere H, Psomas C, Guiller E, Chatron M, Cristol J, Badiou S. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate 60 mL/min per 1.72 m2. AIDS 2013; 27: 1295-302.

156. Fabri M, Ruzic M, Lendak D, Preveden T, Fabri I, Petric V. Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin. Srp Arh Celok Lek 2013; 141: 320-4.

157. Donato M, Banfi G, Cresseri D, Fogazzi G, Martin P, Messa P, Fabrizi F. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review. Int J Artif Organs 2013; 36: 367-72.

158. Maruyama S, Koda M, Oyake N, Sato H, Fuji Y, Horie Y, Murawaki Y. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 2013; 58: 11-5.

159. Chen Y, Chiou W, Hung S, Su Y, Hwang S. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrology 2013; 14: 187.

160. Lin M, Chiu Y, Lee C, Yu H, Chen H, Wu M, Hwang S. Factors associated with CKD in the elderly and nonelderly population. Clin J Am Soc Nephrol 2013; 8: 33-40.

161. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85: 1019-27.

162. Fabrizi D, Dixit V, Messa P. Interferon mono-therapy for symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. Acta Gastro-Enterol Belg 2013, 76: 363-71.

163. Fabrizi F, Plasisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 2013; 61: 623-37.

164. Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208: 1240-9.

165. Gordovskaia N, Kozlovskaia L, Milavanova S, Ignatova T, Korotchaeva I. Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment. Ter Arkh 2013; 85: 78-84.

166. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, Haberl A, et al. End-stage renal disease and dialysis in HIV-positive patients: observations form a long-term cohort study with a follow-up of 23 years. HIV Medicine 2013; 14: 127-35.

167. Cao Y, Gong M, Han Y, Xie J, Li X, Zhang L, Li Y, et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in mainland China: a multicenter cross-sectional study. Nephrology 2013; 18: 307-12.

168. Mauro E, Gattei V, Mazzaro C. Recombinant human erythropoietic and granular colony stimulating factor in hepatitis C virus related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. Infez Med 2014; 22: 337-41.

169. Ble M, Aguilera V, Rubin A, Vinaixa C, Prieto M, Berenguer M. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl 2014; 20: 25-34.

170. Fabrizi F, Messa P, Martin P. The unravelled link between chronic kidney disease and hepatitis C infection. New J Science 2014; 180203.

171. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20: 7544-54.

172. Fabrizi F, Messa P, Martin P. Novel evidence on hepatitis C virus-associated glomerular disease. Kidney Int 2014; 86: 466-9.

173. Fabrizi F, Donato F, Messa P. Hepatitis C virus infection and glomerular disease. Minerva Urol Nefrol 2014; 66: 139-49.

174. De Nicola S, Aghemo A, Campise M, D’Ambrosio R, Rumi M, Messa P, Colombo M. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther 2014; 19: 517-31.

175. Banerjee T, Scherzer R, Powe N, Steffick D, Shanihnian V, Saran R, Pavkov M, et al. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immun Defic Syndr 2014; 67: 145-52.

176. Petta S, Macaluso F, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more ? Gut 2014; 63: 369-75.

177. Lee J, Lin M, Chang J, Hung C, Chang J, Chen H, Yu M, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. Plos One 2014; 9: e100790.

178. Zeng Q, Gong Y, Dong S, Xiang H, Wu Q. Association between exposure to hepatitis B virus and chronic kidney disease in China. Int Med Res 2014; 42: 1178-84.

179. Li W, Lee Y, Chen I, Wang S, Hsiao C, Loke S. Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease. J Viral Hepatitis 2014; 21: 706715.

180. Chen Y, Lin H, Li C, Lee M, Su Y. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014, 85: 1200-7.

181. Hsu Y, Lin J, Ho H, Kao Y, Huang Y, Hsiao N, Wu M, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302.

182. Humphries K, Darling J, Barritt A. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: A case series and review of the literature. Dig Dis Sci 2014; 59: 2007-12.

183. Stine J, Cornella S, Shah N. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis 2014; 73: e64.

184. Hsieh M, Lu P, Kuo M, Lin W, Lin C, Lai C, Tsai J, et al. Prevalence and associated factors with chronic kidney disease in human immunodeficiency –infected patients in Taiwan. J Microbiol Immunol Infect 2015; 48: 256-62.

185. Makara M, Sulyok M, Csacsovski O, Sulyok Z, Valyu –Nagy I. Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir, and ribavirin: A case report. J Clin Virol 2015; 72: 66-8.

186. Ennaifer R, Sabbah M, Hefaiedh R, Romdhane H, Cheikh M, Belhadj N. Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis, and low-grade malignant lymphoma: a challenge? La Tunisie Medicale 2015; 93: 203-4.

187. Cornella S, Stine J, Kelly V, Caldwell S, Shah N. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgraduate Medicine 2015; 127: 413-7.

188. Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, Stasi C, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. Hepatology 2015; 61: 1145-53.

189. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, Karras A, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62: 24-30.

190. Su S, Lin C, Kao S, Wu C, Lu K, Lai C, Yang H, et al. Risk factors and their interaction on chronic kidney disease: a multicentre case control study in Taiwan. BMC Nephrology 2015; 16: 83.

191. Mazzaro C, Panarello G, Mauri E, Gattei V, Pozzato G. Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. Dig Dis Sci 2015; 47: 613-6.

192. Morisue A, Fukuoka K, Goto R, Ota K, Yamashita H, Shinno Y, Yamadori I. Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring haemodialysis that improved with virus removal and eradication using double- filtration plasmapheresis without interferon. CEN Case Rep 2015; 4: 38-42.

193. Molnar M, Alhourani H, Wall B, Lu L, Streja E, Kalantar-Zadeh K, Kovesdy C. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 2015; 61: 1495-502.

194. Chen Y, Hwang S, Li C, Wu C, Lin C. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risks of chronic kidney disease. Medicine (Baltimore) 2015; 94: e1334.

195. Fabrizi F, Martin P, Cacoub P, Messa P, Donato F. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother 2015; 16: 1815-27.

196. Negro F, Forton D, Craxì A, Sulkowski M, Feld J, Manns M. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015; 149: 1345-60.

197. Kurbanova N, Qayyum R. Association of hepatitis C virus infection with proteinuria and glomerular filtration rate. Clin Transl Sci 2015; 8: 421-24.

198. Elshahawi Y, Sany D, Abd Elmohsen W, Tantawi T. Microalbuminuria and pegylated interferon in hepatitis C patients. Saudi J Kidney Dis Transpl 2015; 26: 1183-9.

199. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney diseases: a systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.

200. Hsu Y, Ho H, Huang Y, Wang H, Wu M, Lin J, Wu C. Association between antiviral treatment and extra-hepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.

201. Krajewska M, Rukasz D, Jakuszko K, Augustyniak –Bartosik H, Penar J, Bednarz Z, Klinger M. Hepatitis C-associated glomerulonephritis mimicking systemic lupus erythematosus. Scand J Rheumatol 2015; 44: 343-44 [letter].

202. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment on the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 2015; 22: 897-905.

203. Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, Li X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget 2017; 8: 10692-702.

204. Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 2016; 10: 415-23.

205. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV –positive patients: Systematic review and meta-analysis. J Med Virol 2016; 88: 487-97.

206. Van der Meer A, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol 2016; 65: S95-S108.

207. Rogal S, Yan P, Rimland D, Lo Re V, Al-Rowais H, Fried L, Butt A, et al. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES. Dig Dis Sci 2016; 61: 930-6.

208. Hwang J, Jiang M, Lu Y, Weng S. Impact of HCV infection on diabetes patients for the risk of end-stage renal failure. Medicine 2016; 95: e2431.

209. Gragnani L, Piluso A, Urraro T, Fabbrizzi A, Fognani E, Petraccia L, Genovesi A, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets 2016; Feb 8. [Epub ahead of print].

210. Sise M, Bloom A, Wisocky J, Lin M, Gustafson J, Lundquist A, Steele D, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemic with direct-acting antiviral agents. Hepatology 2016; 63: 408-17.

211. Saadoun D, Thibault V, Si Ahmed S, Alric L, Mallet M, Guillaud C, Izzedine H, et al. Sofosbuvir plus ribavirin for hepatitis C virus –associated cryoglobulinemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75: 1.

212. Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S, Saracino A, et al. Incidence ad predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV co-infected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis 2016; 35: 1511-20.

213. Ferri C, Ramos-Casals M, Zignego A, Arcaini P, Roccatello D, Antonelli A, Saadoun D, et al. ISG-EHCV Coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 2016; 15: 1145-60.

214. Petta S, Maida M, Macaluso F, Barbara M, Licata A, Craxi A, Camma C. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 2016; 150: 145-55.

215. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016; 150: 1599-608.

216. Berenguer J, Rodriguez-Castellano E, Carrero A, Von Wichmann M, Montero M, Galindo M, Mallolas J, et al. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017; 66: 344-56.

217. Mahale P, Engels A, Li R, Torres H, Hwang L, Brown E, Kramer J. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 2017; doi: 10.1136/gutjnl-2017-313983.

218. Sise M, Backman E, Ortiz G, Hundemer G, Ufere N, Chute D, Brancale J, et al. Effect of sofosbuvir –based hepatitis C virus therapy on kidney function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2017; 12: 1615-23.

219. Johnson R, Shimada M. Contemporary management of hepatitis C in patients with chronic kidney disease. Clin J Am Soc Nephrol 2017; 12: 1563-65.

220. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152: 142-56.

221. Kupin W. Viral-associated glomerulonephritis: Hepatitis C and HIV. Clin J Am Soc Nephrol 2017; 12: 337-1342.

222. Lai T, Lee M, Yang H, You S, Lu S, Wang L, Yuan Y, et al. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. Kidney Int 2017; http://dx.doi.org/10.1016/j.kint.2017.03.02.

223. Lai T, Lee M, Yang W, You S, Lu S, Wang L, Yuan Y, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology 2017; 66: 784-93.

224. Park H, Chen C, Wang W, Henry L, Cook R, Nelson D. Chronic hepatitis C increases the risk of chronic kidney disease while effective treatment decreases the incidence of CKD. Hepatology 2017 Sep 5. doi: 10.1002/hep.29505 [Epub ahead of print].

225. Petta S. Hepatitis C virus and cardiovascular: A review. J Advanced Res 2017; 8: 161-80.

226. Lin M, Chen T, Lin W, Liu C, Hsieh Y, Chiu W, Chang C, et al. Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease- a nationwide cohort study. BMC Gastroenterology 2017; 17: 99.

227. Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, et al. A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep 2017; 6: 55-60.

228. Martin P, Fabrizi F. Benefit of direct-acting antiviral therapy for cyroglobulinemia due to hepatitis C infection. Am J Gastroenterol 2017; 112: 1309-10.

229. Fabrizi F, Donato F, Messa P. Hepatitis C and its metabolic consequences in kidney disease. Ann Hepatol 2017; 16: 851-61.

230. Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell A, Hull M, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis 2017; 17: 246.